healthneutral
PIV and Endometrial Cancer: What the Numbers Tell Us
Sunday, July 12, 2026
Study Cohort
- 101 women
- Surgery dates: Aug 2022 – Aug 2024
Key Measure
| Metric | What It Is | How It Was Used |
|---|---|---|
| Pan‑immune Inflammation Value (PIV) | Composite score of immune cells and inflammation markers | Measured pre‑op; higher scores linked to worse outcomes |
| Systemic Immune‑Inflammation Index (SII) | Neutrophil × Platelet / Lymphocyte | Elevated in poorer outcome group |
| Systemic Inflammatory Response Index (SIRI) | Neutrophil × Monocyte / Lymphocyte | Elevated in poorer outcome group |
| CD4+/CD8+ Ratio | Helper vs. cytotoxic T cells | Higher ratio protective |
Patient Groups
- Poor Outcome Group
- Older average age
- Larger tumors, advanced stages
- Higher neutrophil‑to‑lymphocyte ratios
- Elevated SII, SIRI, and PIV scores
- Better Outcome Group
- More likely to have had pre‑operative chemotherapy
- Higher percentages of CD4+ T cells
- Higher CD4+:CD8+ ratio
Statistical Findings
- Raised PIV → independent predictor of worse prognosis.
- Higher CD4+ T cells / higher CD4+:CD8+ ratio → reduced risk of poor outcomes.
- A logistic regression model using these variables achieved good predictive accuracy for post‑surgical results.
Limitations & Future Work
- Modest sample size
- Short follow‑up period (6 months)
Authors’ Call to Action
Larger, longer studies are needed to confirm these findings and refine predictive tools for endometrial cancer patients.
Actions
flag content
